Indivumed, a pioneering biotech company in precision oncology, has announced a strategic partnership with the University of Rochester Medical Center (URMC) to enhance the discovery of novel cancer therapeutics. This collaboration, revealed on December 10, 2025, aims to leverage Indivumed’s expertise in standardized tissue and clinical data collection to accelerate research and development efforts focused on patient-centric cancer treatments.
Collaboration Aims for Patient-Centric Innovations
The partnership will utilize Indivumed’s innovative platform, which is based on meticulously curated surgical tissue samples and comprehensive clinical data. By adhering to rigorous standard operating procedures, URMC will contribute its expertise in collecting and processing high-quality biosamples. A key aspect of this collaboration is the commitment to minimizing ischemia time to under ten minutes, ensuring the integrity and quality of samples for research purposes.
The joint research efforts will prioritize the creation of well-characterized, patient-derived tumor models (PDTMs). These models, which include classical cell cultures, spheroids, and organoids, will be instrumental in advancing the identification and validation of pharmaceutical targets for cancer treatment. According to Dr. Hartmut “Hucky” Land, Deputy Director of the Wilmot Cancer Institute, this collaboration builds on a successful history of working with Indivumed. He stated, “The new project will create greater opportunities to identify new therapeutics and biomarkers, uncover insights on the right target-patient match for clinical decision-making, and thus help advance cancer care.”
Focus on High-Need Cancer Types
Initially, the collaboration will target advanced stages of solid tumors with significant medical needs, including colorectal cancer, pancreatic cancer, lung cancer, and breast cancer. As the partnership progresses, there is potential for expansion into other cancer types.
This collaboration not only enhances Indivumed’s ongoing research initiatives but also provides valuable insights for clinicians involved in therapeutic decision-making. Hartmut Juhl, CEO and founder of Indivumed, expressed his enthusiasm for the partnership, stating, “We are thrilled to deepen our collaboration with URMC, significantly enhancing our ability to identify novel cancer therapeutics in a truly patient-centered approach.”
The University of Rochester Medical Center is now part of the Indivumed Global Clinical Network, which includes numerous prestigious hospitals and oncology institutes across North America, Europe, and Asia. This partnership builds upon previous successful collaborations, including a recent publication that explored a novel classification method for different types of colon cancer.
Both organizations share a vision for advancing cancer care through innovative research and collaboration, striving to ensure that every cancer patient has access to the most effective therapeutic options available.
